Tag Archives: Eylea

September, 2018

August, 2018

November, 2017

  • 27 November

    Regeneron Drops Eylea Combination After Phase 2 Failures

    TARRYTOWN, N.Y., Nov. 27, 2017 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that results from two Phase 2 studies that added the angiopoietin2 (Ang2) antibody nesvacumab to EYLEA® (aflibercept) Injection did not provide sufficient differentiation to warrant Phase 3 development. The RUBY study evaluated patients with diabetic macular edema (DME) and the ONYX study …

March, 2015